Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
-
Published:2024-05
Issue:3
Volume:19
Page:359-370
-
ISSN:1776-2596
-
Container-title:Targeted Oncology
-
language:en
-
Short-container-title:Targ Oncol
Author:
Rimini Margherita, Masi Gianluca, Lonardi Sara, Nichetti Federico, Pressiani Tiziana, Lavacchi Daniele, Jessica Lucchetti, Giordano Guido, Scartozzi Mario, Tamburini Emiliano, Pastorino Alessandro, Rapposelli Ilario Giovanni, Daniele Bruno, Martinelli Erika, Garajova Ingrid, Aprile Giuseppe, Schirripa Marta, Formica Vincenzo, Salani Francesca, Winchler Costanza, Bergamo Francesca, Balsano Rita, Gusmaroli Eleonora, Lorenzo Angotti, Landriscina Matteo, Pretta Andrea, Toma Ilaria, Pirrone Chiara, Diana Anna, Leone Francesco, Brunetti Oronzo, Brandi Giovanni, Garattini Silvio Ken, Satolli Maria Antonietta, Rossari Federico, Fornaro Lorenzo, Niger Monica, Zanuso Valentina, De Rosa Antonio, Ratti Francesca, Aldrighetti Luca, De Braud Filippo, Foti Silvia, Rizzato Mario Domenico, Vivaldi Caterina, Stefano Cascinu, Rimassa Lorenza, Antonuzzo Lorenzo, Casadei-Gardini AndreaORCID
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367–83. https://doi.org/10.1080/17474124.2021.1991313. 2. Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983–2007) and predictions to 2030. Gastroenterology. 2018;154(6):1719-1728.e5. https://doi.org/10.1053/j.gastro.2018.01.033. 3. Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–14. https://doi.org/10.1016/j.jhep.2019.03.013. 4. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61. 5. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84. https://doi.org/10.1016/S1470-2045(20)30109-1.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|